Drugs / YPEG-IFN α-2a
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT01327729 Comparator | Nov 2010 → Apr 2011 | chronic hepatitis C virus infection | BioGeneric Pharma | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YPEG-IFN α-2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01327729 ↗ |
| Known as | pegylated interferon alpha 2a | “pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg” NCT01327729 ↗ |
| Modality | Protein / enzyme biologic | “pegylated interferon” NCT01327729 ↗ |
| Route | Subcutaneous | “YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group” NCT01327729 ↗ |